Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.43 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446472 | 0.98 | TSHR (0.47) | TSHRL3MBTL1CYP1A2CHRM2CHRM4 | |
| SCHEMBL11670116 | 0.96 | L3MBTL1 (0.49) | TSHRL3MBTL1CYP1A2CHRM2CHRM4 | |
| SCHEMBL24322679 | 0.96 | L3MBTL1 (0.49) | TSHRL3MBTL1CYP1A2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL344831 | 0.96 | TSHR (0.46) | TSHRL3MBTL1CYP1A2CHRM2CHRM4 | |
| SCHEMBL34585 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL344817 | 0.89 | TSHR (0.52) | TSHRCYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL1447146 | 0.86 | TSHR (0.44) | TSHRL3MBTL1CYP1A2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL4056528 | 0.84 | TSHR (0.43) | TSHRL3MBTL1CYP1A2CHRM2CHRM4 | |
| SCHEMBL3512713 | 0.84 | L3MBTL1 (0.46) | TSHRL3MBTL1CYP1A2CHRM2CHRM4 | |
| Oxalic Acid SCHEMBL12465627 | 0.82 | KMT2A (0.57) | TSHRPIK3CDKMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116927-A1 | Synthesis of GLP-1R/GIPR Agonists and Precursors Thereof | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| EP-4731645-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS AND PRECURSORS THEREOF | Carmot Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2024264014-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS AND PRECURSORS THEREOF | CARMOT THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | claimed |
| US-20260116927-A1 | Synthesis of GLP-1R/GIPR Agonists and Precursors Thereof | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4731645-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS AND PRECURSORS THEREOF | Carmot Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024264014-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS AND PRECURSORS THEREOF | CARMOT THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-3768294-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | Carmot Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112236161-A | Modulators of G protein-coupled receptors | 卡莫特治疗学股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-8846647-B2 | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8748415-B2 | C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2670765-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | Bristol-Myers Squibb Company (US) | 2013-12-11 | — | — | EP | disclosed |
| EP-2670764-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-07 | — | — | US | disclosed |
| US-20130029954-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| WO-2012106190-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012106188-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | CHRM2 701/4885CHRM3 450/4885ACHE 1335/4885 |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, CDK17 | CHRM2 4718/4885CHRM3 3445/4885ACHE 4422/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | CHRM2 781/4885CHRM3 510/4885ACHE 1483/4885 |
| US-20130029954-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BET1, ERG28, CD4 | CHRM2 3417/4885CHRM3 2108/4885ACHE 4364/4885 |
| US-20260116927-A1 | Synthesis of GLP-1R/GIPR Agonists and Precursors Thereof | GLP1R, GIPR, GRPR | CHRM2 2317/4885CHRM3 2054/4885ACHE 4333/4885 |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | CHRM2 4774/4885CHRM3 3796/4885ACHE 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.